133 results
8-K
EX-99.2
FOLD
Amicus Therapeutics Inc
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
of their work and what they contribute to the community Career Development Reimagined performance management process to measure the what and the how, rewarding … Manufacturing and Related GHG Emissions Diversity, Equity, & Inclusion (DEI) 580 Volunteer hours (U.S.): 22 Amicus-supported community programs: 32
8-K
EX-99.2
FOLD
Amicus Therapeutics Inc
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
from both switch and naïve patients Robust interest from physician community and treatment centers LAUNCH DYNAMICS
22 U.S. Update and Market … satisfaction in their job, are proud of their work and what they contribute to the community Career Development Reimagined performance management
S-3ASR
6e4pwpdv6eshzm
8 Nov 23
Automatic shelf registration
5:25pm
8-K
EX-99.2
c2w4e
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-10.1
trhcm04w4nk03ta7g0ez
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-99.1
7j4azba8q8nn
28 Sep 23
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
12:00pm
8-K
EX-99.1
rt3kjzlh4qtg
27 Sep 23
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023
7:00am
8-K
EX-99.1
80rv2gz5 f4ayc9
21 Aug 23
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
7:01am
8-K
EX-99.1
8sbrbe
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
8-K
EX-99.2
dzl0vl2f2b
8 Aug 23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
EX-99.1
49enz9vn
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
8-K
EX-10.1
22b6pr4
12 May 23
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-99.2
iphtdnxo5qw4zbgdcg
10 May 23
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
7:01am
8-K
EX-99.1
elb23lut
26 Apr 23
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
2:04pm
8-K
EX-99.1
zpeng9 6sw
16 Dec 22
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
8:17am